Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07684612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Trial sites expanded: 1 → 8 locations
    • Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
  2. Trial status: Not Yet Recruiting to Recruiting Show 4 more changesShow less
    • Study sites: 1 to 8
    • Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
    • Eligibility criteria expanded, about 43 words
    • Secondary endpoints: details revised at 4 of 19 entries
  3. Study sites: 0 to 1v3
  4. Collaborator revisedv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.
Trial Details
NCT Number NCT07684612
Lead Sponsor GlaxoSmithKline
Collaborators: GOG, ENGOT, APGOT
Conditions
(from sponsor)		 Ovarian Neoplasms
Related terms Ovarian Neoplasms
Enrollment 690 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov